Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / y mabs therapeutics omburtamab crl hits hard but all

YMAB - Y-mAbs Therapeutics: Omburtamab CRL Hits Hard But All Is Not Over

Y-mAbs Therapeutics Inc.

Summary

  • Last year, the FDA hit YMAB with a CRL for its neuroblastoma drug omburtamab.
  • The company will need to do a new trial to get approval.
  • Their restructuring will get them through mid-2024 with existing cash.

For further details see:

Y-mAbs Therapeutics: Omburtamab CRL Hits Hard, But All Is Not Over
Stock Information
Company Name: Y-mAbs Therapeutics Inc.
Stock Symbol: YMAB
Market: NASDAQ
Menu
YMAB YMAB Quote YMAB Short YMAB News YMAB Articles YMAB Message Board
Get YMAB Alerts

News, Short Squeeze, Breakout and More Instantly...